S&P 5007,722.60▲0.6% Nasdaq26,477.81▲1.2% Dow52,377.57▲0.0% Russell 2K2,818.87▲1.2% 10-Yr4.99%+1bp VIX17.52−0.87 WTI$100.46▼1.3% Gold$4,079.60▲1.0% EUR/USD1.113▼0.4% BTC$77,594▼0.2% Nikkei64,131▲3.1%
At close · Wed, Oct 28, 2026
Daily Market Updates.

US Markets

Home›US Markets›Equities›A pharma giant is moving past one patent cliff , but a…

A pharma giant is moving past one patent cliff , but another is already looming

Reported · Written up by our desk · Equities

Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.

← Newer storyFelippe Astrachan appointed AvlaRe CEO, André Bertolino to lead Avla…

More like this

US MarketsThe Market Isn’t Buying Skydance’s Balance-Sheet Math
US MarketsEuropean TTF Gas Is Back Above 100 Euros a Megawatt-Hour
US MarketsAmazon falls 7%, Intel plunges 25% in premarket trading, as pressure mounts after earnings
US Markets‘Elite North Korean hackers’ blamed for $6.3bn Binance heist – business live
US Markets‘There’s a lot of hurt between us’: My father’s caregiver is using his debit card for DoorDash orders. What can I do?

Sources

CNBC MarketsA pharma giant is moving past one patent cliff , but another is already looming
CNBC WorldA pharma giant is moving past one patent cliff , but another is already looming

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.